2,136 Shares in IQVIA Holdings Inc. (NYSE:IQV) Purchased by Strategic Investment Advisors MI

Strategic Investment Advisors MI acquired a new position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 2,136 shares of the medical research company's stock, valued at approximately $377,000.

A number of other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of IQVIA by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock valued at $3,956,087,000 after acquiring an additional 105,504 shares during the period. Canada Pension Plan Investment Board lifted its position in IQVIA by 20.0% during the fourth quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after purchasing an additional 712,958 shares in the last quarter. Geode Capital Management LLC grew its holdings in IQVIA by 1.9% during the fourth quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock valued at $818,315,000 after purchasing an additional 77,981 shares during the period. Invesco Ltd. increased its position in IQVIA by 53.4% in the fourth quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after buying an additional 902,226 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of IQVIA by 2.5% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock worth $481,380,000 after buying an additional 59,426 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Redburn Partners set a $188.00 target price on shares of IQVIA in a report on Friday, May 23rd. Citigroup reiterated a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Hsbc Global Res cut shares of IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Finally, UBS Group cut their price target on IQVIA from $255.00 to $185.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. Eight analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Price Performance

Shares of IQVIA stock traded down $0.30 during trading hours on Friday, reaching $157.86. The company's stock had a trading volume of 237,949 shares, compared to its average volume of 1,648,680. The firm has a 50 day moving average price of $148.98 and a 200-day moving average price of $174.85. The company has a debt-to-equity ratio of 2.19, a current ratio of 0.82 and a quick ratio of 0.82. The stock has a market cap of $27.31 billion, a P/E ratio of 21.49, a P/E/G ratio of 1.74 and a beta of 1.28. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The company had revenue of $3.83 billion during the quarter, compared to the consensus estimate of $3.77 billion. During the same period last year, the company earned $2.54 earnings per share. IQVIA's revenue was up 2.5% on a year-over-year basis. On average, analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.